Safety and Efficacy of Hartone in Stable Angina Pectoris - An Open Comparative Trial

Padmaja U. Kumar, Prabha Adhikari, Pratibha Pereira, Parvathi Bhat

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objectives : to evaluate the safety and efficacy of 'Hartone' - a proprietary herbal product primarily containing Terminalia arjuna in stable angina pectoris patients. • Patients and Methods : Ten patients with stable angina pectoris were given Hartone 2 caps twice daily for 6 weeks and 1 cap twice daily for the next 6 weeks. Haematological and biochemical investigations to assess safety were carried out on day 0, day 42 and day 84. Serum lipid profile was done before and after therapy. Efficacy was assessed by considering the reduction in the number of anginal episodes and improvement in stress test. The results were compared with 10 patients of stable angina pectoris on isosorbide mononitrate (ISMN) 20 mg twice daily. Results : Hartone afforded symptomatic relief in 80% of patients and ISMN in 70%. The number of anginal attacks were reduced from 79/wk to 24/wk by Hartone and from 26/wk to 7/wk by ISMN. Although patients of both groups showed improvement in several stress test parameters compared to base line, the difference was not statistically significant. Hartone improved BP response to stress test in two patients and ejection fraction in one. Hartone was better tolerated than ISMN and showed no evidence of hepatic or renal impairment. Its effects on lipid profile was not consistent. Conclusion : Hartone is a safe and effective anti-anginal agent comparable to ISMN and is better tolerated. Large scale, randomised, double blind trials are needed to prove its efficacy.

Original languageEnglish
Pages (from-to)685-689
Number of pages5
JournalJournal of Association of Physicians of India
Volume47
Issue number7
Publication statusPublished - 01-07-1999
Externally publishedYes

Fingerprint

isosorbide-5-mononitrate
Stable Angina
Safety
Exercise Test
Terminalia
Lipids
Kidney
Liver

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Kumar, Padmaja U. ; Adhikari, Prabha ; Pereira, Pratibha ; Bhat, Parvathi. / Safety and Efficacy of Hartone in Stable Angina Pectoris - An Open Comparative Trial. In: Journal of Association of Physicians of India. 1999 ; Vol. 47, No. 7. pp. 685-689.
@article{19a895062e5a47689b7403326c4c3bb7,
title = "Safety and Efficacy of Hartone in Stable Angina Pectoris - An Open Comparative Trial",
abstract = "Objectives : to evaluate the safety and efficacy of 'Hartone' - a proprietary herbal product primarily containing Terminalia arjuna in stable angina pectoris patients. • Patients and Methods : Ten patients with stable angina pectoris were given Hartone 2 caps twice daily for 6 weeks and 1 cap twice daily for the next 6 weeks. Haematological and biochemical investigations to assess safety were carried out on day 0, day 42 and day 84. Serum lipid profile was done before and after therapy. Efficacy was assessed by considering the reduction in the number of anginal episodes and improvement in stress test. The results were compared with 10 patients of stable angina pectoris on isosorbide mononitrate (ISMN) 20 mg twice daily. Results : Hartone afforded symptomatic relief in 80{\%} of patients and ISMN in 70{\%}. The number of anginal attacks were reduced from 79/wk to 24/wk by Hartone and from 26/wk to 7/wk by ISMN. Although patients of both groups showed improvement in several stress test parameters compared to base line, the difference was not statistically significant. Hartone improved BP response to stress test in two patients and ejection fraction in one. Hartone was better tolerated than ISMN and showed no evidence of hepatic or renal impairment. Its effects on lipid profile was not consistent. Conclusion : Hartone is a safe and effective anti-anginal agent comparable to ISMN and is better tolerated. Large scale, randomised, double blind trials are needed to prove its efficacy.",
author = "Kumar, {Padmaja U.} and Prabha Adhikari and Pratibha Pereira and Parvathi Bhat",
year = "1999",
month = "7",
day = "1",
language = "English",
volume = "47",
pages = "685--689",
journal = "The Journal of the Association of Physicians of India",
issn = "0004-5772",
publisher = "Journal of Association of Physicians of India",
number = "7",

}

Safety and Efficacy of Hartone in Stable Angina Pectoris - An Open Comparative Trial. / Kumar, Padmaja U.; Adhikari, Prabha; Pereira, Pratibha; Bhat, Parvathi.

In: Journal of Association of Physicians of India, Vol. 47, No. 7, 01.07.1999, p. 685-689.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Safety and Efficacy of Hartone in Stable Angina Pectoris - An Open Comparative Trial

AU - Kumar, Padmaja U.

AU - Adhikari, Prabha

AU - Pereira, Pratibha

AU - Bhat, Parvathi

PY - 1999/7/1

Y1 - 1999/7/1

N2 - Objectives : to evaluate the safety and efficacy of 'Hartone' - a proprietary herbal product primarily containing Terminalia arjuna in stable angina pectoris patients. • Patients and Methods : Ten patients with stable angina pectoris were given Hartone 2 caps twice daily for 6 weeks and 1 cap twice daily for the next 6 weeks. Haematological and biochemical investigations to assess safety were carried out on day 0, day 42 and day 84. Serum lipid profile was done before and after therapy. Efficacy was assessed by considering the reduction in the number of anginal episodes and improvement in stress test. The results were compared with 10 patients of stable angina pectoris on isosorbide mononitrate (ISMN) 20 mg twice daily. Results : Hartone afforded symptomatic relief in 80% of patients and ISMN in 70%. The number of anginal attacks were reduced from 79/wk to 24/wk by Hartone and from 26/wk to 7/wk by ISMN. Although patients of both groups showed improvement in several stress test parameters compared to base line, the difference was not statistically significant. Hartone improved BP response to stress test in two patients and ejection fraction in one. Hartone was better tolerated than ISMN and showed no evidence of hepatic or renal impairment. Its effects on lipid profile was not consistent. Conclusion : Hartone is a safe and effective anti-anginal agent comparable to ISMN and is better tolerated. Large scale, randomised, double blind trials are needed to prove its efficacy.

AB - Objectives : to evaluate the safety and efficacy of 'Hartone' - a proprietary herbal product primarily containing Terminalia arjuna in stable angina pectoris patients. • Patients and Methods : Ten patients with stable angina pectoris were given Hartone 2 caps twice daily for 6 weeks and 1 cap twice daily for the next 6 weeks. Haematological and biochemical investigations to assess safety were carried out on day 0, day 42 and day 84. Serum lipid profile was done before and after therapy. Efficacy was assessed by considering the reduction in the number of anginal episodes and improvement in stress test. The results were compared with 10 patients of stable angina pectoris on isosorbide mononitrate (ISMN) 20 mg twice daily. Results : Hartone afforded symptomatic relief in 80% of patients and ISMN in 70%. The number of anginal attacks were reduced from 79/wk to 24/wk by Hartone and from 26/wk to 7/wk by ISMN. Although patients of both groups showed improvement in several stress test parameters compared to base line, the difference was not statistically significant. Hartone improved BP response to stress test in two patients and ejection fraction in one. Hartone was better tolerated than ISMN and showed no evidence of hepatic or renal impairment. Its effects on lipid profile was not consistent. Conclusion : Hartone is a safe and effective anti-anginal agent comparable to ISMN and is better tolerated. Large scale, randomised, double blind trials are needed to prove its efficacy.

UR - http://www.scopus.com/inward/record.url?scp=0033156112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033156112&partnerID=8YFLogxK

M3 - Article

VL - 47

SP - 685

EP - 689

JO - The Journal of the Association of Physicians of India

JF - The Journal of the Association of Physicians of India

SN - 0004-5772

IS - 7

ER -